莱斯康制药 LXRX 深 沪
等待开盘 09-02 09:30:00 美东时间
2.19
-0.060
-2.67%
华盛通- 最 高2.2689
- 今 开2.24
- 成交量 198.79万股
- 最 低 2.17
- 昨 收 2.25
- 总市值 9.74亿
- 52周最高 2.68
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 1.06
- 委 比 67.72%
- 总股本 4.45亿
- 历史最高 19.62
- 量 比 0.71
- 振 幅 4.40%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon earns third $10M Novo milestone
Lexicon Pharmaceuticals (LXRX) said it earned a third $10M milestone payment from Novo Nordisk after reaching a patient-dosing milestone in the Phase 1 trial of obesity drug candidate LX9851. The paym...
08-24 20:42
Lexicon 2026年第二季度财报：许可收入未重现，营收降至69.2万美元
Lexicon（LXRX）2026年第二季度营收69.2万美元，稀释每股亏损0.07美元，期末现金及投资1.906亿美元；上年许可收入未再出现，公司由盈转亏。
08-07 01:49
Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-06 20:46
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $692.000 ...
08-06 19:48
Lexicon Pharmaceuticals LXRX 暴涨9.6% 借生物科技板块涨势触及五十二周高点
莱克西肯制药（LXRX）当日大涨9.6%，收盘接近2.53美元的52周高点，开盘价2.28美元，日内最高触及2.51美元，当日成交量1321613股，换手率0...
06-26 22:42
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX
JR Research sees Amazon (AMZN) as a compelling opportunity, citing its massive $464 billion backlog and dominant position in the AI compute boom. Super Micro Computer (SMCI) also receives a more favor...
05-28 01:05
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.
05-11 23:10
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals has secured a $100 million loan facility from Hercules Capital to enhance financial flexibility and support upcoming milestones. The initial $55 million will repay an existing loan, with additional tranches available upon achieving specific milestones. The facility features an 18-month interest-only period and a floating rate of prime plus 3.1%, maturing in 2030. Lexicon's CFO highlighted the deal's benefits for accessing ...
05-04 20:05
Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg
04-17 20:02
